ARCT · Arcturus Therapeutics Holdings Inc. · Webcasts, Transcripts & Audio
$13.57
+0.54 (+4.14%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$389.82M
Shares
28.42M
Volume · Oct 5
460.09K
Avg daily vol (3M)
919.97K
Arcturus Therapeutics Holdings Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Arcturus Therapeutics Holdings Inc. (ARCT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲448.6%
$13.37M
−$35.27M
'22 Q3
22-11-09
▲2666.5%
$160.29M
$117.35M
'22 Q4
23-03-28
▲1431%
$80.28M
$50.75M
'23 Q1
23-05-09
▼61.2%
$10.52M
−$52.55M
'23 Q2
23-08-07
▲237.6%
$45.14M
−$16.22M
'23 Q3
23-11-14
▼80.8%
$30.86M
−$11.71M
'23 Q4
24-03-07
▼52.7%
$38.01M
−$26.82M
'24 Q1
24-05-08
▲374%
$49.86M
−$17.22M
'24 Q2
24-08-05
▼7.7%
$41.67M
−$6.90M
'24 Q3
24-11-07
▼26.2%
$22.77M
−$30.00M
'24 Q4
25-03-06
▼22.7%
$29.38M
−$14.08M
'25 Q1
25-05-12
▼43.2%
$28.30M
−$9.18M
'25 Q2
25-08-11
▼58.8%
$17.15M
−$13.45M
'25 Q3
25-11-10
▼68.4%
$7.20M
−$29.08M
'25 Q4
26-03-03
▼93%
$2.06M
−$26.96M
'26 Q1
26-05-07
LATEST
▼89.5%
$2.96M
−$23.79M
'26 Q2
26-08-06
Investor Update
Investor event
2026-09-23
Arcturus Therapeutics Holdings Inc. (ARCT) September 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
Arcturus Therapeutics Holdings Inc. (ARCT) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call
Revenue
$2.96M
▼ 89.5% YoY Diluted EPS
$-0.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Positive tone
OTC Deficiency / ARCT-810 Program
Cystic Fibrosis / ARCT-032 Program
Regulatory Progress with FDA
Revenue
$2.06M
▼ 93% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Positive tone
ARCT-032 cystic fibrosis Phase II
ARCT-810 OTC deficiency development
STARR sa-mRNA platform validation
Revenue
$7.20M*
▼ 68.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Positive tone
Clinical Trial Enrollment Expansion
ARCT032 Cystic Fibrosis Program
Costave COVID-19 Vaccine
Revenue
$17.15M
▼ 58.8% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Call Transcript
Positive tone
ARCT-032 Cystic Fibrosis program
FDA regulatory alignment and Phase III planning
ARCT-810 OTC deficiency program
Revenue
$28.30M
▼ 43.2% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript
Positive tone
ARCT-810 OTC deficiency program
KOSTAIVE COVID-19 vaccine commercialization
ARCT-032 Cystic Fibrosis Phase 2
Revenue
$29.38M
▼ 22.7% YoY Diluted EPS
$-0.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript
Positive tone
ARCT-032 Cystic Fibrosis Program
Meiji KOSTAIVE Sales Shortfall
KOSTAIVE Vaccine Approvals and Commercialization
Revenue
$22.77M*
▼ 26.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript
Confident tone
KOSTAIVE commercial launch in Japan
Arcalis manufacturing strategic asset
ARCT-032 cystic fibrosis program
Revenue
$41.67M
▼ 7.7% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript
Confident tone
ARCT-032 cystic fibrosis therapeutic
ARCT-810 OTC deficiency program
Kostaive COVID-19 vaccine launch and regulatory progress
Revenue
$49.86M
▲ 374% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript
Confident tone
Quadrivalent seasonal influenza vaccine program
Kostaive COVID-19 vaccine commercialization in Japan
ARCT-810 OTC deficiency program
Revenue
$38.01M
▼ 52.7% YoY Diluted EPS
$-1.00
▼ 153.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
Confident tone
Kostaive COVID-19 Vaccine Approval and Launch
Manufacturing and Partnerships (CSL, Meiji, ARCALIS)
LUNAR-FLU (ARCT-2138) Seasonal Influenza Program
Revenue
$30.86M*
▼ 80.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript
Revenue
$45.14M
▲ 237.6% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2023 Earnings Call Transcript
Revenue
$10.52M
▼ 61.2% YoY Diluted EPS
$-1.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2023 Earnings Call Transcript
Revenue
$80.28M
▲ 1431% YoY Diluted EPS
$1.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call Transcript
Revenue
$160.29M*
▲ 2666.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
Revenue
$13.37M
▲ 448.6% YoY Diluted EPS
$-1.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2022 Earnings Call Transcript
Revenue
$27.09M
▲ 1254% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2022 Earnings Call Transcript
Revenue
$5.24M
▲ 146.5% YoY Diluted EPS
$-1.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2021 Earnings Call Transcript
Revenue
$5.79M
▲ 158.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2021 Earnings Call Transcript
Revenue
$2.44M
▲ 4.5% YoY Diluted EPS
$-2.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2021 Earnings Call Transcript
Revenue
$2.00M
▼ 13.8% YoY Diluted EPS
$-2.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2021 Earnings Call Transcript
Revenue
$2.13M
▼ 19.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2020 Earnings Call Transcript
Revenue
$2.24M
▼ 24.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2020 Earnings Call Transcript
Revenue
$2.33M
▼ 29.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2020 Earnings Call Transcript
Revenue
$2.32M
▼ 77.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript
Revenue
$2.65M
▼ 39.2% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-11
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2019 Earnings Call
Revenue
$2.97M
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts